These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9401941)

  • 1. Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice.
    Rentsch KM; Schwendener RA; Schott H; Hänseler E
    J Pharm Pharmacol; 1997 Nov; 49(11):1076-81. PubMed ID: 9401941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes.
    Rentsch KM; Schwendener RA; Schott H; Hänseler E
    J Chromatogr B Biomed Appl; 1995 Nov; 673(2):259-66. PubMed ID: 8611960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
    Koller-Lucae SK; Schott H; Schwendener RA
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1572-80. PubMed ID: 9316874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
    Schwendener RA; Horber DH; Odermatt B; Schott H
    J Cancer Res Clin Oncol; 1996; 122(2):102-8. PubMed ID: 8576276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
    Schwendener RA; Schott H
    J Cancer Res Clin Oncol; 1996; 122(12):723-6. PubMed ID: 8954169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
    Horber DH; Schott H; Schwendener RA
    Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
    Schwendener R; Schott H
    Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne.
    Horber DH; Cattaneo-Pangrazzi RM; von Ballmoos P; Schott H; Ludwig PS; Eriksson S; Fichtner I; Schwendener RA
    J Cancer Res Clin Oncol; 2000 Jun; 126(6):311-9. PubMed ID: 10870640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
    Koller-Lucae SK; Schott H; Schwendener RA
    Br J Cancer; 1999 Jul; 80(10):1542-9. PubMed ID: 10408395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
    Yoshida T; Kobayashi K; Okabe Y; Okumura H; Matano S; Kanno M; Takeda Y; Ohtake S; Nakamura S; Matuda T
    J Clin Pharmacol; 1994 Jan; 34(1):52-9. PubMed ID: 8132852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.
    Schwendener RA; Friedl K; Depenbrock H; Schott H; Hanauske AR
    Invest New Drugs; 2001; 19(3):203-10. PubMed ID: 11561676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.
    Kodama K; Morozumi M; Saitoh K; Kuninaka A; Yoshino H; Saneyoshi M
    Jpn J Cancer Res; 1989 Jul; 80(7):679-85. PubMed ID: 2507491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes.
    Horber DH; Ottiger C; Schott H; Schwendener RA
    J Pharm Pharmacol; 1995 Apr; 47(4):282-8. PubMed ID: 7791024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
    Ueda T; Nakamura T; Kagawa D; Uchida M; Domae N; Sugiyama M; Ueda Y; Sasada M; Uchino H
    Cancer Chemother Pharmacol; 1989; 24(6):371-5. PubMed ID: 2791191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
    Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
    Schott H; Schwendener RA
    Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
    Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
    J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.